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Background. Increased incidence of cancer was frequently reported in scleroderma (SSc), but no association with gynaecological
malignancies was described in literature. Objectives. To investigate gynaecological neoplasms in SSc patients. Methods. In this
cross-sectional analysis, we evaluated 80 SSc patients, living in the same geographical area. We considered all patients undergoing
gynaecological evaluation, including pap test as screening for cervical cancer, between January 2008 and December 2014. Results.
55 (68.7%) patients were negative and 20 (25%) presented inflammatory alterations, while cancer or precancerous lesions were
found in 5 (6.2%) cases (2 showed cervical cancer (one of them in situ), 1 vulvar melanoma, 1 vulvar intraepithelial neoplasia,
and 1 endocervical polyp with immature squamous metaplasia). The frequency of cervical cancer in our series seems higher in
comparison to the incidence registered in the same geographical area. The presence of atypical cytological findings correlated with
anti-Scl70 autoantibodies (p = 0.022); moreover, the patients with these alterations tended to be older (median 65, range 46–67),
if compared to the whole series (p = 0.052). Conclusions. A relatively high frequency of gynaecological malignancies was found in
our SSc series. In general, gynaecological evaluation for SSc women needs to be included in the routine patients’ surveillance.
1. Introduction
Increased incidence of malignancies was widely reported in
systemic sclerosis (SSc) [1]. In particular, a strong association
with lung cancer and, less frequently, with haematological
neoplasms was described [2]. As for other autoimmune
diseases, it is not surprising that the chronic inflammation
and the abnormal tissue reparative processes increase the
risk of malignancy, particularly in target organs such as
sclerodermic lungs. Nonetheless, a relationwith breast cancer
was suggested, even if it remains controversial, since only a
few epidemiological studies found it [3]. By contrast, an asso-
ciation with the cancer of the uterine cervix was not reported
in literature, considering that cervical uterus malignancy is
one of the most frequent cancers in women worldwide [4].
Because of its high frequency, public health programs of
screening for cervical cancer have been established in several
countries, in order to identify precancer lesions or to treat
the disease at an earlier stage [5]; the conventional cytological
Papanicolaou test (pap test) is recommended every 3 years for
all women between 21 and 65 years old [6].
The aim of the present study is to investigate the results
of pap test in a cohort of SSc women, who underwent the
screening for cervical cancer.
2. Patients and Methods
In this cross-sectional analysis, we included all SSc patients
who underwent gynaecological screening for malignancies,
including pap test, during the period between January 1, 2008,
and December 31, 2014. Namely, we evaluated 80 women
(mean age 51.2±12 years and disease duration 7.9±5.8 years
at the end of the study), referring to our University-Based
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Table 1: Clinical features and pap test screening findings in 80 SSc patients.
SSc series Normal Inflammation Atypical cells/cancer 𝑝 values
(𝑛 = 80) A (𝑛 = 55) B (𝑛 = 20) C (𝑛 = 5) (A versus C) (A + B versus C)
Age at onset 51.2 ± 12 51.2 ± 12 51.2 ± 12 65 (46–67) 0.052 0.06
SSc duration 7.9 ± 5.8 8 ± 5.8 8 ± 5.8 6 (1–13) 0.45 0.45
Skin subsets
Limited 72 (90%) 50 (90.9%) 18 (90%) 4 (80%) 0.42 0.42
Diffuse 8 (10%) 5 (9%) 2 (10%) 1 (20%) 0.42 0.42
Serology
Anti-Scl70 23 (28.7%) 17 (30.9%) 2 (10%) 4 (80%) 0.046 0.022
ACA 37 (46.2%) 28 (50.9%) 8 (40%) 1 (20%) 0.35 0.37
ANoA 14 (17.5%) 6 (10.9%) 8 (40%) 0 1 0.58
Digital ulcers 29 (36.2%) 21 (38.2%) 7 (35%) 1 (20%) 0.64 0.65
Interstitial lung disease 30 (37.5%) 22 (40%) 8 (40%) 0 0.15 0.15
FVC < 70% 4 (5%) 3 (5.4%) 0 1 (20%) 0.30 0.23
DLCO < 70% 46 (57.5%) 32 (58.2%) 12 (60%) 2 (40%) 0.65 0.65
PAH 0
History of smoking 27 (33.7%) 16 (29.1%) 9 (45%) 2 (40%) 0.63 1
History of immunosuppressant 5 (6.2%) 4 (7.3%) 1 (5%) 0 1 1
Pap test
Negative 55 (68.7%)
Inflammatory alterations 20 (25%)
Atypical cells/cancer 5 (6.2%)
Rheumatology Centre, living in the same geographical area
of the province of Modena (Northern Italy). In all cases the
diagnosis of SSc was made by trained rheumatologists; any-
way, all patients fulfilled the 2013 ACR/EULAR classification
criteria for SSc [7].
Clinical records of epidemiological, clinical, serological,
and instrumental data of all SSc patients along with analytic
reports of the gynaecological evaluationwere available for the
study. Epidemiological data on cervical cancer were available
online from Tumour Registry of the Province of Modena [8].
Statistical analysis was performed in order to investi-
gate the possible associations between SSc parameters and
cytological findings at pap test. Values are given as mean ±
SD for normally distributed variables, or as median (range)
for not normally distributed variables. Group values and
proportions were compared by univariate analysis of variance
(ANOVA) and Fisher’s exact test, respectively.The significant
level adopted was <5%.
3. Results
Eighty patients presented at least one cytological evaluation
of the cervix at the end of the study period. At pap test
evaluations, 55 (68.7%) patients were negative and 20 (25%)
presented inflammatory alterations consistent with chronic
cervicitis, while atypical cells related to cervical cancer were
found in 2 (2.5%) cases, namely, a carcinoma in situ (CIN
III) in one and invasive malignancy in the other one. In the
remaining 3 patients the histological evaluation revealed a
vulvarmelanoma, a vulvar intraepithelial neoplasia (VIN III),
and an endocervical polyp with immature squamous meta-
plasia, respectively. Overall, 5/80 (6.5%) SSc patients showed
precancerous/cancerous lesions of the cervix or external
genital organs (Table 1).
The age of our SSc patients with neoplastic lesions was 65
years (range: 46–67). Data from the Cancer Registry of our
province [8] show that the higher incidence of cervical cancer
regards the age groups 30–44 and 45–59. Therefore, our SSc
patients with cancer were older than what we expect based on
our reference population.
The frequency of cervical cancer in our series (2 cases)
seems to be higher than expected, considering the incidence
registered in the same geographical area and in the same
time period (standardized rate 8.0 cases, 95% CI 5.2–10.7,
out of 100,000 inhabitant-years) [8]. In fact, in the province
of Modena, the cumulative risk to develop a cervical cancer
during the entire life (0–74 years) is 0.6%, with a median age
at diagnosis of 51 years [8]; thus, in our series of 80 patients
followed up for 7.9 ± 5.8 years, we should expect less than
1 case (0.48 cases) of malignancy of the cervix. However,
both the limited SSc series evaluated and the low number
of cervical cancers observed did not permit obtaining a
standardized incidence ratio (observed/expected events, SIR)
with statistical significance.
In addition, the presence of atypical cytological findings
correlated with serum anti-Scl70 autoantibodies (4/5 versus
19/75;𝑝 = 0.022), while patients with these alterations tended
to be older (median 65, range 46–67), if compared to the
whole series (𝑝 = 0.052). No statistical associations with skin
or visceral SSc manifestations, smoking history, or treatment
with immunosuppressors were found.
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Table 2: Cervical or vulvar cancers in SSc patients: review of the literature.
First author, year [ref.] Country Type of study patient-years1 (pts/follow-up) Cervical cancer Vulvar cancer
Duncan, 1979 [9] Mayo Clinic, USA Cohort study (2,141/n.d.2) 10 1
Lee, 1983 [10] Canada Cohort study (95/7.3 ± 6.6) 2 0
Kyndt, 1997 [11] France Cohort study (123/median 4) 1 0
Hill, 2003 [12] South Australia Registry-based (441/6.1 ± 2.8) 5 0
Chatterjee, 2005 [13] Detroit area, USA Registry-based 4,908 3 (2 in situ) 0
Derk, 2006 [14] Pennsylvania, USA Cohort study 3,775 4 1
Olesen, 2010 [15] Denmark Registry-based 16,003 9 0
Airo’, 2011 [16] Italy Cohort study 4,041 1 1
Belloli, 2011 [17] Italy Cohort study (112/n.d.3) 34 0
Szekanecz, 2012 [18] Hungary Cohort study (218/n.d.) 1 0
Moinzadeh, 2014 [19]5 United Kingdom Cohort study (2,177/median 12.8) 17 “gynaecological” cases
Shah, 2015 [20]6 John Hopkins H, USA Cross-sectional (1,044/1990–2012) 3 1
Present series Italy Cohort study 560 2 (1 in situ) 2 (1 in situ)
(1) When the number of patient-years is not reported, number of patients (pts) and number of years of follow-up are indicated in parenthesis. (2) Authors
reviewed histories of SSc patients seen between 1959 and 1975. (3) Authors indicated that the follow-up was approximately from 2004 to November 2009. (4)
Uterine cancers. n.d.: not done. (5)This study considered the database of SSc patients followed at the Centre for Rheumatology and Connective Tissue Diseases
of the Royal Free Hospital, London. The “gynaecological” cases of cancer were not better defined, and were not classified either before or after SSc onset. (6)
This study evaluated the database of SSc patients observed at the John Hopkins Scleroderma Centre, Baltimore, in the period from 1990 to 2012. Other 5 cases
of cancer of the endometrium were cited.
All SSc series studied included male patients, except our cohort.
In our study, 2 cases of cervical cancer and 2 cases of vulvar cancers were found, as reported; the further case who presented an endocervical polyp with
immature squamous metaplasia is not indicated.
4. Review of the Literature
To the best of our knowledge, no other studies in literature
focused on cervical or vulvar cancer in SSc. Nonetheless,
sporadic cases of these types of tumours are frequently cited
in the list of the malignancies found during registry-based or
cohort studies (Table 2) [9–18].
In a study regarding a large SSc series [9] seen at theMayo
Clinic between 1959 and 1975, 10 cases of cervical cancer were
reported; curiously, in 5 cases the diagnosis of the tumour and
the diagnosis of SSc were made in the same year, suggesting
possible paraneoplastic cases. One case of vulvar carcinoma
was also reported.
In a population-based cohort of 441 SSc patients from
South Australia [12], 5 cervical cancers were signalled out
of 90 cases of neoplasms registered. However, authors did
not evaluate this finding by statistical analysis because of
the small number of patients developing this malignancy.
In another registry-based study on 538 SSc patients from
the Detroit metropolitan area [13], 3 women with cervical
cancer were found, 1 invasive and 2 in situ, in the absence
of significantly increased incidence compared to general
population. In a study evaluating a large series of 769 SSc
patients prospectively followed up between 1987 and 2002 for
the development of cancer [14], cervical cancer was recorded
in 4/62 cases of malignancy observed after SSc diagnosis; one
tumour of the vulva was also noticed. Again, the incidence
of cervical-vulvar cancer observed in this patients series
(5/769, 0.6%) was quite comparable to that reported in
general population. Consistently, in the Danish nationwide
population-based cohort study by Olesen et al. [15], among
162 cases of cancer in 1,586 female SSc patients, 9 cases
of cervical cancer were observed (SIR 1.5, 95% CI 0.7–2.8).
No cases of cervical cancer were registered in 2 large cohort
studies in Japan [21] and Taiwan [22].
On the contrary, data of 218 SSc patients followed up
in a Hungarian University-Based Centre [18] evidenced 10
patients with malignancies; one of them was a 53-year-
old woman with cervical cancer. Authors indicated that the
SIR versus general population was 37.0, but the interval of
confidence was not calculated, so that the finding cannot be
reliable.
Two recent studies [19, 20] on large SSc cohorts from the
databases of highly specialised centres identified few cases of
gynaecological cancers; however, these studies were designed
for other purposes than the analysis of the incidence of the
malignancies.
In 2009, Bernatsky et al. [23] investigated the history
of an abnormal pap test by self-administrated questionnaire
in a Canadian multicentre cohort of 320 SSc women. The
lifetime prevalence of an abnormal pap test was 25.4%, com-
pared to 13.8% reported in the Canadian general population;
moreover, a significant positive association with diffuse skin
subset, smoking history, and younger age was noted. Even if
a detection bias could influence these findings (SSc patients
may be more likely to be aware of comorbidities than general
population), authors concluded that it seems prudent to
ensure adequate attention to cervical cancer screening for SSc
women.
5. Discussion
We evidenced an apparently high frequency of cancerous
lesions of the cervix or the vulva in our cohort of SSc patients.
The increase of the incidence of cervical/vulvar cancer in SSc
4 International Journal of Rheumatology
is not reported by the world literature; however, the present
study is the first to specifically investigate the incidence of
gynaecological (cervical and vulvar) tumours in patients with
SSc, while the other studies found in literature (Table 2)
are focused on research of every type of tumours (mainly
infiltrating and life-threatening cancers); nonetheless, they
are characterized by heterogeneous designs and are based on
different population subsets. Therefore, it could be assumed
that in SSc women the appearance of cervical or vulvar
cancers, particularly in situ lesions (i.e., CIN and VIN III),
could be underestimated in large cohort or registry studies. In
fact, in our series, 3/5 SSc patients with abnormal cytological
tests did not present cervical cancer, but other pathological
conditions thatwere generally excluded from the studies cited
above, because of their low frequency.
Given these considerations, even if the cervical cancer,
as specific clinical entity, may be considered as frequent as
in the general population, periodic gynaecological screening
for (pre)cancerous lesions of female genital organs should
be carried out, since their occurrence might be not so
uncommon in the course of SSc.
Pap smear abnormalities were also searched in other
autoimmune disorders: in a case-control study [24] on 118
women affected mainly by systemic lupus erythematosus and
rheumatoid arthritis, the frequency of abnormal pap tests
was significantly higher in the patients (8.1% and 9.3%, resp.)
compared to controls (1.7%); authors concluded that it might
be an association between the autoimmune diseases and
occurrence of (pre)cancer lesions of the cervix.
The main known trigger of cervical cancer is the human
papillomavirus (HPV); in particular, a few specific virus
genotypes are considered carcinogenetic [25]. Consequently,
an increased risk of cervical cancer in SSc women, if con-
firmed, might indicate an increased infection/persistence of
HPV in scleroderma patients. In this regard, no consistent
data may be found in literature. Indeed, only one study [26]
investigated the presence HPV infection and/or dysplasia in
a small cohort of 31 SSc women; comparable frequencies of
the virus versus healthy controls were noticed, but infection
by 2 or more HPV types was 2 times more frequent in SSc
patients.The possibility of a link between SSc andHPV needs
to be deeply studied.
Finally, the possibility of a selection bias with the conse-
quent risk to overestimate cervical cancer incidence cannot
be excluded. However, our data on pap test regarded less
than 2-thirds of the SSc women population from province of
Modena. Yet, considering the findings of the Italian National
Centre of Epidemiology, Surveillance and Health Promotion
in the “Passi 2012” study [27], more than 75% of the women
interviewed affirmed that they underwent a pap test in the
last 3 years. This discrepancy points out to the possible risk
that SSc patients, who are affected by a chronic disease with
necessity to undergo a number of clinical and instrumental
exams, could overlook other medical evaluations (such as the
pap test), considered erroneously not so necessary for their
peculiar health condition.Nonetheless, also family physicians
might undervalue the screening exams recommended for
general population for their highly “medicalised” female
patients.Thus, even though an increased incidence of cervical
cancer cannot be unequivocally affirmed by our study, it
should be remembered to pay attention also to this medical
aspect in SSc women, in order to ensure the bestmedical care,
even if not directly related to scleroderma.
6. Conclusions
In our SSc patients’ series, we found a relatively high fre-
quency of cancerous lesions of the cervix by means of pap
test. A significant association between gynaecological malig-
nancies and anti-Scl70 autoantibodies was also found. These
preliminary findings need to be verified in larger controlled
epidemiological studies. In general, periodic gynaecological
screening for SSc patients is truly suggested.
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